This paper reports that phosphoglycerate kinase 1 PGK1 moonlights as a nonenzymatic co-adaptor for AP-2 mediated endocytosis: PGK1 binds AP-2alpha via a DKF 290-292 motif, stabilizes AP-2 complex levels (proteasome dependent), directly recognizes dileucine and tyrosine sorting motifs on TfR and EGFR, and together with AP-2 and clathrin increases cargo recruitment and internalization; kinase activity is dispensable for this role (kinase-dead PGK1 rescues)
Reasoned synthesis: the combination of direct biochemical interaction data between purified PGK1 and AP-2alpha, cargo motif binding assays (including mutation of cargo motifs), liposome reconstitution showing increased membrane recruitment when both cargo peptide and AP-2 are present, and functional rescue with kinase-dead PGK1 makes a strong case that PGK1 acts as a co-adaptor for a subset of AP-2 cargoes in these cell systems. The remaining mechanistic unknown is how PGK1 stabilizes AP-2 against proteasomal degradation mechanistically; this does not invalidate the main claim but identifies the next mechanistic gap
Conceptually, this study expands the catalog of moonlighting glycolytic enzymes with direct roles in membrane trafficking, linking metabolic enzymes to vesicle coat biology. Practically, identifying PGK1 as an AP-2 co-adaptor suggests new ways to modulate receptor internalization and surface receptor levels (eg EGFR) and could intersect with disease contexts in which PGK1 expression or modification is altered (cancer, kidney disease) β though therapeutic translation would require careful separation of its enzymatic and adaptor functions
Conclusion: The experimental evidence supports the model that PGK1 acts as a nonenzymatic co-adaptor with AP-2alpha to recognize sorting motifs, stabilize AP-2 complex levels, and promote AP-2/clathrin-dependent endocytosis of TfR and EGFR in cultured human cells. Confidence: high for the described cell biological mechanism in these systems; moderate for generalization to all AP-2 cargoes or in vivo contexts until genetic and in vivo validations are performed
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.